Results 101 to 110 of about 1,665,519 (290)

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka   +6 more
wiley   +1 more source

The psychometric properties of validated tools to assess cannabis use disorder: A systematic review and meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung   +8 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

open access: yesAddiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin   +3 more
wiley   +1 more source

CANNABINOIDS REGULATE TYPE 1 CANNABINOID RECEPTOR EXPRESSION IN CELL CULTURE MODELS OF HUNTINGTON'S DISEASE

open access: yes, 2012
Type 1 cannabinoid receptor (CB1) levels decline in the striatum of animal models of Huntington’s disease (HD) and in the brains of human patients suffering from HD prior to other pathogenic changes.
Laprairie, Robert
core  

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

open access: yesAddiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria   +10 more
wiley   +1 more source

Identification and quantification of Δ‐9‐tetrahydrocannabinol and the synthetic cannabinoid MDMB‐4en‐PINACA in edible products seized by United Kingdom police in 2024

open access: yesAddiction, EarlyView.
Abstract Background and aims Cannabis edible products are increasingly being sold on the illicit market around the world. Use of these products, typically labelled as containing Δ‐9‐tetrahydrocannabinol (THC), has been linked to adverse health effects, particularly amongst adolescents.
Matthew Gardner   +9 more
wiley   +1 more source

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

open access: yesAddiction, EarlyView.
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke   +5 more
wiley   +1 more source

Association between prenatal cannabis and tobacco co‐exposure and cognition in childhood: Insights from the US adolescent brain cognitive development study

open access: yesAddiction, EarlyView.
Abstract Background and aims While evidence on the individual effects of prenatal cannabis and tobacco exposure on offspring cognition is accumulating, their combined impact remains understudied. Therefore, we examined the interaction between prenatal cannabis and tobacco exposure on fluid (e.g. reasoning abilities) and crystallized (e.g.
Mathilde Argote   +2 more
wiley   +1 more source

Toxicokinetic modelling of the synthetic cannabinoid 5F‐MDMB‐P7AICA and its main metabolite in pigs following pulmonary administration

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Since their emergence on the drug market, synthetic cannabinoids (SC) are still gaining increasing importance in forensic toxicology. The representatives of the so‐called new psychoactive substances have in common that they have not undergone preclinical safety studies. Hence, knowledge on toxicokinetic (TK) data is sparse.
Adrian A. Doerr   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy